Consistency in the Distribution of Bethesda System for Reporting Thyroid Cytology Categories Over 9 Years: A Single Institute, Retrospective Study
Authors' conclusion
BSRTC showed consistency throughout the study across all observed categories. An overlap between AUS and benign may exist, possibly due to the heterogenic definition of AUS as reflected in the 2023 BSRTC subclassification for AUS.
Study context
- Population
- Patients who underwent FNA for a thyroid nodule with a documented Bethesda System for Reporting Thyroid Cytopathology (BSRTC) classification, single institution, 2010–2018
- Participants
- 2,830 thyroid nodules
- Outcome
- Difference in the rates of BSRTC categories II–VI (benign, AUS, follicular neoplasm, suspicious for malignancy, malignant) between the study years
- Follow-up
- 2010–2018
Methodological detailssingle-centre, chart review
- Single-centre
- Chart review
Main finding
As reported in the abstract
Change in BSRTC II–VI category rates across study years (2010–2018)
BSRTC II-VI distribution, respectively
83.9% (2373), 8.2%, (232), 2.7% (75), 3.3% (93), and 2.0% (57)
Observational data: associations, not effects.
Further findings
Benign cytology rate (BSRTC II), 2011 vs 2015 and 2018
- Significant change in benign rate between 2011 and 2015 and 2018
- P < 0.005
Atypia of undetermined significance (AUS) rate (BSRTC III), 2011 vs 2015 and 2018
- Significant change in AUS rate between 2011 and 2015 and 2018
- P < 0.005
Original publication
Consistency in the Distribution of Bethesda System for Reporting Thyroid Cytology Categories Over 9 Years: A Single Institute, Retrospective Study. Endocr Pract. Published 2 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →